The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study
Articolo
Data di Pubblicazione:
2022
Abstract:
Patients with inflammatory bowel disease (IBD) have a high risk of developing extra-intestinal manifestations (EIMs). We aimed to assess the cumulative incidence and clinical course of EIMs in patients treated with Vedolizumab (VDZ) and non-gut selective biologic drugs.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
TNF inhibitors; Ustekinumab; Vedolizumab; biologic therapy; extra-intestinal manifestations (EIMs); inflammatory bowel disease
Elenco autori:
Ferretti, Francesca; Monico, Maria Camilla; Cannatelli, Rosanna; Carmagnola, Stefania; Lenti, Marco Vincenzo; Di Sabatino, Antonio; Conforti, Francesco; Pastorelli, Luca; Caprioli, Flavio; Bezzio, Cristina; Saibeni, Simone; Mazza, Stefano; Vecchi, Maurizio; Maconi, Giovanni; Ardizzone, Sandro
Link alla scheda completa:
Pubblicato in: